Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results